阅读说明：本技术 一种改善肠道微生态失调的葛花提取物 (Flos puerariae extract for improving intestinal micro-ecological imbalance ) 是由 叶梓 陈旭 王建智 侯龙辉 于 2021-01-20 设计创作，主要内容包括：本发明涉及一种改善肠道微生态失调的葛花提取物。具体地,本发明提供一种葛花提取物的用途,用于制备组合物,所述的组合物用于改善肠道微生态失调。本发明所述的葛花提取物能够用于预防和治疗口服抗生素导致的肠道菌群失调。(The invention relates to a pueraria flower extract for improving intestinal micro-ecological imbalance. Specifically, the invention provides application of a pueraria flower extract in preparing a composition for improving intestinal micro-ecological disorder. The pueraria lobata flower extract can be used for preventing and treating intestinal dysbacteriosis caused by oral antibiotics.)

1. Use of a pueraria flower extract for the preparation of a composition for ameliorating intestinal dysbiosis;

the pueraria flower extract is prepared by the following method:

(1) extracting flos Puerariae Lobatae with alcohol water solution to obtain alcohol water extractive solution;

(2) concentrating the alcohol-water extracting solution, adding an organic solvent for extraction, and removing the solvent by vacuum distillation of the organic phase to obtain the pueraria flower extract, wherein the organic solvent comprises one or more of petroleum ether, chloroform and ethyl acetate.

2. The use as claimed in claim 1, wherein the pueraria flower extract is prepared by the following method:

adding 55-65% (v/v) ethanol water solution 6-10 times the amount of flos Puerariae Lobatae, heating and reflux extracting for 4-8 hr, filtering, concentrating the filtrate under reduced pressure to obtain concentrated solution, adding petroleum ether into the concentrated solution for extraction, distilling the obtained petroleum ether organic phase layer under reduced pressure to remove solvent, and drying to obtain flos Puerariae Lobatae extract.

3. The use of claim 1, wherein the amelioration of intestinal dysbiosis comprises amelioration of intestinal dysbiosis.

4. The use according to claim 3, wherein the flora is selected from the group consisting of: bifidobacteria, lactobacilli, or combinations thereof.

5. The use according to claim 3, wherein the gut dysbiosis comprises oral antibiotic induced gut dysbiosis.

6. The use according to claim 3, wherein the gut flora imbalance comprises a decrease in gut flora caused by oral administration of an antibiotic.

7. A composition comprising the pueraria lobata extract of claim 1 and arabinose.

8. The composition of claim 7, wherein the composition is yogurt.

9. Use of a composition according to claim 7 for the preparation of a preparation for improving intestinal dysbiosis.

10. An antibiotic preparation comprising an antibiotic and the pueraria lobata flower extract of claim 1.

Technical Field

The invention relates to the field of food and medicine, in particular to a pueraria flower extract for improving intestinal micro-ecological disorder.

Background

The intestinal tract has a plurality of beneficial bacteria, the antibiotics also have a wide killing or inhibiting effect on intestinal microorganisms in the treatment process, so that intestinal tract flora imbalance is caused, the intestinal tract flora imbalance is a serious side effect which is often caused by oral antibiotics, and the intestinal tract flora imbalance can cause various diseases, such as diarrhea, abdominal pain, abdominal distension, dyspepsia, inflammatory bowel disease, depression and the like, and brings pain to patients. Especially, oral antibiotics have killing or inhibiting effects on some beneficial intestinal bacteria such as bifidobacteria and lactobacilli, and seriously reduce beneficial physiological effects such as digestion promoting and the like of the beneficial bacteria such as the bifidobacteria and the lactobacilli in intestinal tracts, thereby causing adverse effects on health.

Therefore, there is a need in the art to develop a drug for improving intestinal dysbacteriosis caused by oral antibiotics, thereby preventing and treating the side effects of intestinal dysbacteriosis caused by oral antibiotics.

Disclosure of Invention

The invention aims to provide a pueraria flower extract which can effectively prevent and treat intestinal dysbacteriosis caused by oral antibiotics.

In a first aspect, the present invention provides the use of a pueraria flower extract for the preparation of a composition for ameliorating intestinal dysbiosis;

the pueraria flower extract is prepared by the following method:

(1) extracting flos Puerariae Lobatae with alcohol water solution to obtain alcohol water extractive solution;

(2) concentrating the alcohol-water extracting solution, adding an organic solvent for extraction, and removing the solvent by vacuum distillation of the organic phase to obtain the pueraria flower extract, wherein the organic solvent comprises one or more of petroleum ether, chloroform and ethyl acetate.

Preferably, the pueraria flower extract comprises a dry extract.

Preferably, the pueraria flower extract is a dry extract.

Preferably, in the alcohol aqueous solution, the alcohol is a C1-C4 lower alcohol.

Preferably, the C1-C4 lower alcohol comprises one or more of methanol, ethanol, propanol and butanol.

Preferably, the alcohol in the aqueous alcohol solution has a volume fraction of 40 to 70%, preferably 50 to 70%, more preferably 55 to 65%, and still more preferably 60%. .

Preferably, the alcohol aqueous solution is an ethanol aqueous solution.

Preferably, the alcohol aqueous solution is an ethanol aqueous solution, and the volume fraction of ethanol in the ethanol aqueous solution is 40-70%, preferably 50-70%, more preferably 55-65%, and still more preferably 60%.

Preferably, in the step (2), the organic solvent includes petroleum ether.

Preferably, the pueraria flower extract is prepared by the following method:

adding 55-65% (v/v) ethanol water solution 6-10 times the amount of flos Puerariae Lobatae, heating and reflux extracting for 4-8 hr, filtering, concentrating the filtrate under reduced pressure to obtain concentrated solution, adding petroleum ether into the concentrated solution for extraction, distilling the obtained petroleum ether organic phase layer under reduced pressure to remove solvent, and drying to obtain flos Puerariae Lobatae extract.

Preferably, the 55-65% (v/v) ethanol aqueous solution is 60% (v/v) ethanol aqueous solution.

Preferably, the pueraria flower extract is prepared by the following method:

(a) weighing 45-55g of pueraria flower, crushing, adding 450ml of 55-65% (v/v) ethanol aqueous solution of 350-;

(b) extracting the concentrated solution obtained in the step (a) with 280-320mL of petroleum ether each time, extracting twice in total, combining petroleum ether layers obtained by two times of separation (namely petroleum ether extraction liquid), removing the petroleum ether by reduced pressure distillation, and drying to obtain the pueraria flower extract.

Preferably, the pueraria flower extract is prepared by the following method:

(a) weighing 50g of pueraria flower, crushing, adding 400ml of 60% (v/v) ethanol water solution, heating, refluxing, extracting for 6 hours, filtering, and concentrating the filtrate under reduced pressure to 100ml to obtain a concentrated solution;

(b) extracting the concentrated solution obtained in the step (a) with 300mL of petroleum ether each time, extracting twice in total, combining petroleum ether layers obtained by two times of separation (namely petroleum ether extract), removing the petroleum ether by reduced pressure distillation, and drying to obtain the pueraria flower extract.

Preferably, said ameliorating intestinal dysbiosis comprises ameliorating intestinal dysbiosis.

Preferably, said flora is selected from the group consisting of: bifidobacteria, lactobacilli, or combinations thereof.

Preferably, the intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, said intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, the gut flora imbalance comprises gut flora imbalance caused by oral administration of antibiotics.

Preferably, said gut flora imbalance comprises a decrease in the number of gut flora resulting from oral administration of an antibiotic.

Preferably, said improving gut flora imbalance comprises increasing the gut flora population.

Preferably, the improvement comprises recovery, enhancement and/or structuring.

Preferably, the antibiotic is selected from the group consisting of: lincomycin hydrochloride, cephradine, or a combination thereof.

Preferably, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5, preferably 0.8-1.2: 0.8-1.2.

Preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.

Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.

Preferably, the composition is in a solid or liquid form.

Preferably, the composition is in the form of oral preparation or injection preparation.

Preferably, the food composition is yoghurt.

Preferably, the composition is in the form of emulsion, tablet, capsule, oral liquid, granule, powder or syrup.

Preferably, the composition further comprises arabinose.

Preferably, the arabinose comprises L-arabinose.

Preferably, the weight ratio of the pueraria flower extract to the arabinose is 1: 5-200, preferably 1: 10-100, more preferably 1: 20-60, more specifically 1: 30-50, more preferably 1: 35-45.

In a second aspect, the present invention provides a composition comprising a pueraria flower extract according to the first aspect of the present invention and arabinose.

Preferably, the arabinose comprises L-arabinose.

Preferably, the composition is a pharmaceutical composition, a food composition or a health care composition.

Preferably, the composition further comprises a pharmaceutically, food or nutraceutical acceptable carrier.

Preferably, the composition is in a solid or liquid form.

Preferably, the composition is in the form of oral preparation or injection preparation.

Preferably, the composition is a food composition, and the food composition is yogurt.

Preferably, the composition is yogurt.

Preferably, the composition is in the form of emulsion, tablet, capsule, oral liquid, granule, powder or syrup.

Preferably, the yoghurt is yoghurt, fermented milk, flavored yoghurt or flavored fermented milk.

Preferably, the weight ratio of the pueraria flower extract to the arabinose is 1: 5-200, preferably 1: 10-100, more preferably 1: 20-60, more specifically 1: 30-50, more preferably 1: 35-45.

Preferably, the content of the pueraria flower extract is 1-99 wt%, preferably 10-90 wt%, more preferably 20-80 wt%, based on the total weight of the composition.

In a third aspect, the present invention provides the use of a composition according to the second aspect of the invention for the preparation of a preparation for ameliorating intestinal dysbiosis.

Preferably, the formulation is an oral formulation.

Preferably, said ameliorating intestinal dysbiosis comprises ameliorating intestinal dysbiosis.

Preferably, said flora is selected from the group consisting of: bifidobacteria, lactobacilli, or combinations thereof.

Preferably, the intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, said intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, the gut flora imbalance comprises gut flora imbalance caused by oral administration of antibiotics.

Preferably, said gut flora imbalance comprises a decrease in the number of gut flora resulting from oral administration of an antibiotic.

Preferably, said improving gut flora imbalance comprises increasing the gut flora population.

Preferably, the improvement comprises recovery, enhancement and/or structuring.

Preferably, the antibiotic is selected from the group consisting of: lincomycin hydrochloride, cephradine, or a combination thereof.

Preferably, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5, preferably 0.8-1.2: 0.8-1.2.

In a fourth aspect, the present invention provides an antibiotic preparation, which comprises an antibiotic and the pueraria flower extract according to the first aspect of the present invention.

Preferably, the antibiotic formulation is an oral formulation.

Preferably, the antibiotic preparation further comprises arabinose.

Preferably, the arabinose comprises L-arabinose.

Preferably, the antibiotic is selected from the group consisting of: lincomycin hydrochloride, cephradine, or a combination thereof.

Preferably, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5, preferably 0.8-1.2: 0.8-1.2.

Preferably, the weight ratio of the pueraria flower extract to the arabinose is 1: 5-200, preferably 1: 10-100, more preferably 1: 20-60, more specifically 1: 30-50, more preferably 1: 35-45.

Preferably, the weight ratio of the antibiotic (such as lincomycin hydrochloride and/or cefradine) to the arabinose is 1: 0.3-0.5.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments.

Detailed Description

The invention discloses a pueraria flower extract which can effectively prevent and treat intestinal dysbacteriosis caused by oral antibiotics. The experimental research of the invention also shows that the pueraria lobata flower extract and the arabinose can synergistically improve the imbalance of intestinal flora such as intestinal lactobacillus, bifidobacteria and the like caused by oral antibiotics.

Term(s) for

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the terms "comprising," "including," and "containing" are used interchangeably and include not only open-ended definitions, but also semi-closed and closed-ended definitions. In other words, the term includes "consisting of … …", "consisting essentially of … …".

As used herein, the "flower of kudzu" is a flower of the leguminous plant kudzu vine lobata (Willd.) Ohwi, kudzu p.

As used herein, the terms "60% (v/v) ethanol" or "60% (v/v) aqueous ethanol" are used interchangeably to refer to an aqueous ethanol solution having a volume fraction of ethanol of 60%, e.g., 60% ethanol is formulated from 60ml absolute ethanol +40ml water.

Flos puerariae lobatae extract and its use

The invention provides a pueraria flower extract, which is preferably a dry extract or a dry extract.

Preferably, the pueraria flower extract of the present invention is prepared by the following method:

(1) extracting flos Puerariae Lobatae with alcohol water solution to obtain alcohol water extractive solution;

(2) concentrating the alcohol-water extracting solution, adding an organic solvent for extraction, and removing the solvent by vacuum distillation of the organic phase to obtain the pueraria flower extract, wherein the organic solvent comprises one or more of petroleum ether, chloroform and ethyl acetate.

Preferably, in the alcohol aqueous solution, the alcohol is a C1-C4 lower alcohol.

Preferably, the C1-C4 lower alcohol comprises one or more of methanol, ethanol, propanol and butanol.

Preferably, the alcohol in the aqueous alcohol solution has a volume fraction of 40 to 70%, preferably 50 to 70%, more preferably 55 to 65%, and still more preferably 60%. .

Preferably, the alcohol aqueous solution is an ethanol aqueous solution.

Preferably, the alcohol aqueous solution is an ethanol aqueous solution, and the volume fraction of ethanol in the ethanol aqueous solution is 40-70%, preferably 50-70%, more preferably 55-65%, and still more preferably 60%.

Preferably, in the step (2), the organic solvent includes petroleum ether.

Typically, the pueraria flower extract is prepared by the following method:

adding 55-65% (v/v) ethanol water solution 6-10 times the amount of flos Puerariae Lobatae, heating and reflux extracting for 4-8 hr, filtering, concentrating the filtrate under reduced pressure to obtain concentrated solution, adding petroleum ether into the concentrated solution for extraction, distilling the obtained petroleum ether organic phase layer under reduced pressure to remove solvent, and drying to obtain flos Puerariae Lobatae extract.

Preferably, the 55-65% (v/v) ethanol aqueous solution is 60% (v/v) ethanol aqueous solution.

Typically, the pueraria flower extract is prepared by the following method:

(a) weighing 45-55g of pueraria flower, crushing, adding 450ml of 55-65% (v/v) ethanol aqueous solution of 350-;

(b) extracting the concentrated solution obtained in the step (a) with 280-320mL of petroleum ether each time, extracting twice in total, combining petroleum ether layers obtained by two times of separation, removing the petroleum ether by reduced pressure distillation, and drying to obtain the pueraria flower extract.

Typically, the pueraria flower extract is prepared by the following method:

(a) weighing 50g of pueraria flower, crushing, adding 400ml of 60% (v/v) ethanol water solution, heating, refluxing, extracting for 6 hours, filtering, and concentrating the filtrate under reduced pressure to 100ml to obtain a concentrated solution;

(b) extracting the concentrated solution obtained in the step (a) with 300mL of petroleum ether each time, extracting twice in total, combining petroleum ether layers obtained by two times of separation (namely petroleum ether extract), removing the petroleum ether by reduced pressure distillation, and drying to obtain the pueraria flower extract.

The invention also provides application of the pueraria flower extract in preparing a composition for improving intestinal micro-ecological disorder.

Intestinal micro-ecological disorder

The pueraria flower extract and the composition can be used for improving intestinal micro-ecological disorder.

Preferably, said intestinal dysbiosis comprises a dysbiosis of the intestinal flora.

Preferably, said ameliorating intestinal dysbiosis comprises ameliorating intestinal dysbiosis.

Preferably, said flora is selected from the group consisting of: bifidobacteria, lactobacilli, or combinations thereof.

Preferably, the intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, said intestinal dysbiosis comprises intestinal dysbiosis caused by oral antibiotics.

Preferably, the gut flora imbalance comprises gut flora imbalance caused by oral administration of antibiotics.

Typically, the gut flora imbalance comprises a decrease in gut flora caused by oral administration of an antibiotic.

Preferably, said improving gut flora imbalance comprises increasing the gut flora population.

Preferably, the improvement comprises recovery, enhancement and/or structuring.

In the present invention, the antibiotic is preferably selected from the group consisting of: lincomycin hydrochloride, cephradine, or a combination thereof.

Preferably, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5, preferably 0.8-1.2: 0.8-1.2.

Composition and use thereof

The invention also provides a composition which can be a pharmaceutical composition, a food composition or a health-care product composition.

The composition also comprises a carrier acceptable in pharmacy, food or health care products.

As used herein, the term "pharmaceutically, comestibly or nutraceutically acceptable carrier" refers to: one or more compatible solid, semi-solid, liquid or gel fillers suitable for human or animal use and of sufficient purity and sufficiently low toxicity.

It is to be understood that, in the present invention, the carrier is not particularly limited and may be selected from materials commonly used in the art, or prepared by a conventional method, or commercially available. Examples of the pharmaceutically acceptable carrier moiety are cellulose and its derivatives (e.g., methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, etc.), polyols (e.g., propylene glycol, glycerin, sorbitol, etc.), emulsifiers (e.g., tween), wetting agents (e.g., sodium laurylsulfate), buffers, chelating agents, thickeners, pH adjusters, transdermal enhancers, colorants, flavors, stabilizers, antioxidants, preservatives, bacteriostats, pyrogen-free water, etc.

In the present invention, the dosage form of the pharmaceutical composition includes, but is not limited to, oral preparations or injectable preparations.

Typically, the composition is in the form of emulsion, tablet, capsule, oral liquid, granule, powder or syrup.

Typically, the composition, formulation or antibiotic formulation of the present invention is yogurt.

Typically, the composition, formulation or antibiotic formulation of the present invention is yoghurt. The pueraria flower extract can be prepared into yoghourt, and intestinal micro-ecological imbalance can be simply and conveniently improved by orally taking the yoghourt.

The yoghourt is a sour and sweet milk beverage, and is a milk product which is prepared by taking milk as a raw material, adding beneficial bacteria (leavening agent) into the milk after pasteurization, fermenting, and then cooling and filling. In the market, most of the yoghourt products are set type, stirring type and fruit taste type added with various auxiliary materials such as fruit juice, jam and the like.

Yoghurts of the invention include, but are not limited to, yogurt, fermented milk, flavored yogurt, or flavored fermented milk.

The yogurt is prepared from raw cow (sheep) milk or milk powder as raw material by sterilizing, inoculating Streptococcus thermophilus and Lactobacillus bulgaricus (Lactobacillus delbrueckii subsp. bulgaricus), and fermenting.

The fermented milk is prepared from raw cow (sheep) milk or milk powder as raw material by sterilizing and fermenting to obtain product with reduced pH value.

The yoghourt of the flavored yogurt is added with other components such as food additives, fruits, vegetables or grains and the like besides milk/milk powder. The milk/milk powder content is more than 80 percent, and the protein content is more than or equal to 2.3 percent.

Besides milk/milk powder, other components are added after inoculation and fermentation of the flavored fermented milk.

Typically, the yoghurt of the invention is a flavoured yoghurt. The flavored yogurt has better taste and is suitable for the main children and the old who improve intestinal microecological disorder.

In a preferred embodiment of the present invention, the composition of the present invention comprises the pueraria flower extract of the present invention.

In another preferred embodiment of the present invention, the composition of the present invention comprises the pueraria flower extract of the present invention and arabinose.

Preferably, the weight ratio of the pueraria flower extract to the arabinose is 1: 5-200, preferably 1: 10-100, more preferably 1: 20-60, more specifically 1: 30-50, more preferably 1: 35-45.

Preferably, the arabinose comprises L-arabinose.

Antibiotic formulations

The invention also provides an antibiotic formulation capable of treating a microbial infection.

In a preferred embodiment of the present invention, the antibiotic preparation of the present invention comprises an antibiotic and the pueraria flower extract of the present invention.

In another preferred embodiment of the present invention, the antibiotic preparation of the present invention further comprises arabinose. Preferably, the arabinose comprises L-arabinose.

Preferably, the antibiotic is selected from the group consisting of: lincomycin hydrochloride, cephradine, or a combination thereof.

Preferably, the weight ratio of the lincomycin hydrochloride to the cefradine is 0.5-1.5:0.5-1.5, preferably 0.8-1.2: 0.8-1.2.

Preferably, the weight ratio of the pueraria flower extract to the arabinose is 1: 5-200, preferably 1: 10-100, more preferably 1: 20-60, more specifically 1: 30-50, more preferably 1: 35-45.

Preferably, the weight ratio of the antibiotic (such as lincomycin hydrochloride and/or cefradine) to the arabinose is 1: 0.3-0.5.

The main technical effects of the invention comprise:

1. the pueraria lobata flower extract can be used for preventing and treating intestinal dysbacteriosis caused by oral antibiotics.

2. The pueraria lobata flower extract and the arabinose can synergistically improve the imbalance of intestinal flora such as intestinal lactobacillus and bifidobacterium caused by oral antibiotics.

3. The pueraria lobata flower extract can be prepared into yoghourt for oral administration and is used for improving the imbalance of intestinal flora such as intestinal lactobacillus and bifidobacterium caused by oral antibiotics.

The invention will be further illustrated with reference to the following specific examples. It should be understood that the following specific examples are provided to illustrate the detailed embodiments and specific procedures, but the scope of the present invention is not limited to these examples.

Example 1

(1) Preparing a pueraria flower extract, wherein the pueraria flower extract is prepared by the following method:

(a) weighing 50g of pueraria flower, crushing, adding 400ml of 60% (v/v) ethanol water solution, heating, refluxing, extracting for 6 hours, filtering, and concentrating the filtrate under reduced pressure to 100ml to obtain a concentrated solution;

(b) extracting the concentrated solution obtained in the step (a) with 300mL of petroleum ether each time, extracting twice in total, combining petroleum ether layers obtained by two times of separation (namely petroleum ether extract), removing the petroleum ether by reduced pressure distillation, and drying to obtain the pueraria flower extract.

(2) Examining the effect of the pueraria lobata extract prepared in this example on the improvement of the intestinal dysbacteriosis

2.1 Experimental methods

Healthy male SD rats are selected, self-adapted for one week after purchase, and randomly divided into a blank control group, a model group, an implementation group 1, an experiment group 2 and an experiment group 3, wherein each group comprises 8 rats. Then, rats in the blank control group are subjected to intragastric administration of physiological saline, rats in the model group, the implementation group 1, the experimental group 2 and the experimental group 3 are subjected to intragastric administration of an antibiotic mixed solution (lincomycin hydrochloride (1g/kg.bw times) and cefradine (1g/kg.bw times) by using the physiological saline, 2 times a day, and after 4 consecutive days, rats in each group are subjected to intragastric administration according to the following administration modes:

blank control group: physiological saline;

model group: physiological saline;

example set 1: flos Puerariae Lobatae extract (10mg/kg. bw. d);

experimental group 2: l-arabinose (0.4g/kg. bw. d);

experimental group 3: flos Puerariae Lobatae extract (10mg/kg. bw.d) + L-arabinose (0.4g/kg. bw.d);

among these, groups 1-3 rats were administered by gavage with physiological saline.

The continuous administration is carried out for 3 days, the administration is carried out once a day, and 24 hours after the last administration, 1g of feces of the ileocecal part of each group of rats are aseptically collected and used for bacterial culture, and the change of intestinal flora of each group of rats is obtained and shown in table 1. Selection of intestinal flora: bifidobacterium, Lactobacillus. The culture medium was inoculated with Lactobacillus (Lbs medium) and Bifidobacterium (Blb medium), respectively. And culturing, and calculating a logarithmic value of Colony Forming Units (CFU) in wet weight of each gram of excrement according to colony morphology and smear analysis results.

Statistical analysis:

metering usingSPSS software is adopted for data analysis, two-by-two comparison is performed by adopting t test, and p is not more than 0.05, so that the statistical significance is achieved.

2.2 results of the experiment

Changes in intestinal flora in ileocecal faeces taken from different groups of SD rats are shown in table 1.

TABLE 1 ileocecal faecal changes in intestinal flora in SD rats from different groups: (lg^CFU/g)

Group of	Bifidobacterium	Lactobacillus strain
			Blank control group	8.57±0.39	8.34±0.40
Model set	6.91±0.27*	6.74±0.28*
			Experimental group 1	7.83±0.32**	7.71±0.36*
Experimental group 2	7.13±0.35*	7.01±0.32**
			Experimental group 3	8.29±0.41**	8.18±0.39**

Note: p <0.05, p <0.01 compared to control.

As can be seen from table 1, the intestinal bifidobacteria and lactobacilli of rats in the model group were significantly decreased compared to the blank control group, indicating that the animal modeling with the antibiotic causing the imbalance of intestinal flora was successful. Compared with the model group, the results of the experimental groups 1 to 3 show that the pueraria flower extract and the L-arabinose can improve the flora quantity of intestinal bifidobacteria and lactobacillus, the pueraria flower extract and the L-arabinose can improve the intestinal flora imbalance caused by oral antibiotics, and the pueraria flower extract and the L-arabinose can synergistically improve the intestinal flora imbalance caused by oral antibiotics.

The above embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.